In 2021, the global retinal disorders treatment market value reached at US$ 9.99 billion and projected to hit US$ 19 billion by 2030, expanding growth at a CAGR of 7.1% from 2022 to 2030.
In 2021, the global retinal disorders treatment market value reached at US$ 9.99 billion and projected to hit US$ 19 billion by 2030, expanding growth at a CAGR of 7.1% from 2022 to 2030.
The market growth is primarily driven by increasing prevalence of retinal disorders worldwide, advancements in technology, including gene therapy and stem-cell therapy, research and development activities, and rising awareness regarding recent research findings and progress made in the retinal disorders treatment market. Market players should focus on research and development activities and continue to explore the potential of different technologies that could be utilized for retinal disorders treatment.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38188
Macular degeneration is of two types: wet age-related macular degeneration and dry age-related macular degeneration. Diabetic retinopathy is one of the common diabetic eye disorders characterized by damaged blood vessels in the retina. The damaged blood vessels and nerves lead to vision impairment, blurring of vision, and eye hemorrhage. If left untreated, it could lead to retinal detachment and blindness.
The global retinal disorders treatment market is projected to expand at a moderate pace due to rise in prevalence of retinal disorders, owing to increase in geriatric patient population, new product launches, high annual cost of therapy (ACOT), and surge in number of eye care centers leading to increased product utilization.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 9.99 billion |
| Revenue Forecast by 2030 | USD 19 billion |
| Growth rate from 2022 to 2030 | CAGR of 7.1% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Indication, Therapeutic Class, Dosage Form, Distribution Channel, Region |
| Companies Covered | Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited |
Rise in Prevalence of Retinal Disorders Due to Increase in Geriatric Patient Population to Drive Global Market
Age is a prominent risk factor for age-related macular degeneration. The risk of developing advanced age-related macular degeneration increases from 2% in people aged between 50 and 59 to nearly 30% for those over 75. The prevalence of other retinal disorders was 93 million people with diabetic retinopathy, 21 million people diabetic macular edema and 28 million people with vision-threatening diabetic retinopathy. Increase in R&D activities, rise in the number of patients suffering from diseases, and rapid expansion of healthcare and biopharmaceutical industries in developed and developing countries are projected to boost advancements in therapies in the AMD treatment market during the forecast period. For instance, Lucentis and Eylea accounted for 2.8% of total pharmaceutical sales in Canada in 2017.
Links Between COVID-19 and Microvascular Alterations to Increase Demand
The onset of the COVID-19 pandemic is expected to have a moderate impact on the overall growth of the global retinal disorders treatment market in 2020. While the major focus is projected to remain toward the discovery of new vaccine, research and development activities in other branches of the medical sectors are likely to continue as per the initial timeline. Research activities are also anticipated to evaluate the presence of retinal alterations among patients suffering from the novel COVID-19 infection. Due to the constant fear of contracting the virus, doctors and specialists are expected to rely on telehealth services. Although the trends suggest that patients are willing to delay retinal disorders treatment due to the ongoing pandemic, the market is likely to show signs of recovery toward the last quarter of 2020.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38188
Macular Degeneration to Dominate Global Market
In terms of indication, the global retinal disorders treatment market has been divided into macular degeneration, diabetic retinopathy, diabetic macular edema, and others. Macular degeneration has been bifurcated into dry macular degeneration and wet macular degeneration. The macular degeneration segment dominated the market in terms of revenue in 2019. The rise in prevalence of macular degeneration is anticipated to drive the segment during the forecast period. For instance, the number of people living with macular degeneration is expected to reach 196 million globally by 2020 and increase to 288 million by 2040.
Anti-VEGF Agents to be Main Therapeutic Class
Based on therapeutic class, the global retinal disorders treatment market has been categorized into anti-VEGF agents and others. The anti-VEGF agents dominated the global retinal disorders treatment market in 2019. Major market products such as Avastin and Eylea are included in the anti-VEGF drug class. Increase in demand for these products in the treatment of retinal disorders and strong product pipeline are likely to drive the segment. However, the others segment, which includes anti-inflammatory drugs, is projected to expand at the highest CAGR from 2020 to 2030. The increase in the use of anti-inflammatory drugs for pain relief is anticipated to augment the segment.
Eye Solutions to be Preferred Dosage Form
In terms of dosage form, the global retinal disorders treatment market has been divided into gels, eye solutions, capsules & tablets, eye drops, and ointments. The eye solutions segment dominated the global retinal disorders treatment market in 2019. However, the eye drops segment is expected to expand at the highest CAGR during the forecast period. The segment is likely to grow at a rapid pace due to increase in demand for eye drops for treatment of retinal diseases in emerging countries such have China, India, and Brazil.
Retail Pharmacies to Emerge as Major Distribution Channel
Based on distribution channel, the global retinal disorders treatment market has been segregated into hospital pharmacies, retail pharmacies, and online sales. The retail pharmacies segment dominated the market in terms of revenue in 2019 due to wide network, ease of access, and diverse product offerings, including prescription and OTC ophthalmic drugs. However, the shift toward the use of electronic payment modes is projected to boost the growth of the online sale segment during the forecast period.
U.S. to Dominate Global Market
The global retinal disorders treatment market has been segmented into five major regions/country: the U.S., Europe, China, Russia, and Rest of the World. The U.S. dominated the global market in 2019, followed by Europe. The U.S. accounted for a major share of the global retinal disorders treatment market in 2019. Well-developed healthcare infrastructure, high healthcare expenditure, and adoption of branded drugs to treat retinal disorder disorders are the key factors attributed to the country’s significant share of the global market.
The retinal disorders treatment market in China is anticipated to expand at a high CAGR from 2020 to 2030. There have been significant unmet medical needs in the region. Furthermore, healthcare expenditure is increasing in developing markets. Key players are making investments to establish their operations in China. This, in turn, is projected to augment the market in the country.
Competition Landscape
Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., and Novartis AG are the three major companies operating in the global retinal disorders treatment market. The global retinal disorders treatment market is fragmented in terms of number of players. Key players in the global market include Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited. New product development through robust R&D activities and mergers & acquisitions are key strategies adopted by these players to gain a competitive advantage in the global retinal disorders treatment market.
Market Segmentation
By Indication
- Macular Degeneration
- Dry Macular Degeneration
- Wet Macular Degeneration
- Diabetic Retinopathy
- Diabetic Macular Edema
- Others (Retinal Vein Occlusion, etc.)
By Therapeutic Class
- Anti-VEGF Agents
- Others (Anti-inflammatory Drugs, etc.)
By Dosage Form
- Gels
- Eye Solutions
- Capsules & Tablets
- Eye Drops
- Ointments
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
By Region
- U.S.
- Europe
- China
- Russia
- Rest of the World (RoW)
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38188
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/